Tenaya Therapeutics (TNYA) Free Cash Flow (2020 - 2026)

Tenaya Therapeutics' Free Cash Flow history runs 7 years deep, the most recent figure standing at -$18.8 million for Q1 2026.

• On a quarterly basis, Free Cash Flow rose 18.76% year-over-year to -$18.8 million in Q1 2026; TTM through Mar 2026 was -$63.4 million, a 24.83% increase from a year earlier, with the FY2025 full-year figure at -$67.7 million, up 24.66% from the prior year.
• Free Cash Flow eased to -$18.8 million in Q1 2026 per TNYA's latest filing, from -$13.9 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$3.7 million in Q4 2022 and bottomed at -$47.3 million in Q3 2022.
• The 5-year median for Free Cash Flow is -$23.1 million (2025), against an average of -$22.6 million.
• Across the five-year window, Free Cash Flow surged 78.16% in 2022 and tumbled 492.03% in 2023, its largest moves.
• Year by year, Free Cash Flow stood at -$3.7 million in 2022, then tumbled by 492.03% to -$21.7 million in 2023, then gained by 22.0% to -$16.9 million in 2024, then increased by 17.56% to -$13.9 million in 2025, then plunged by 34.65% to -$18.8 million in 2026.
• Per Business Quant, the three latest TNYA Free Cash Flow figures stand at -$18.8 million (Q1 2026), -$13.9 million (Q4 2025), and -$14.5 million (Q3 2025).